AMA and moziware to Revolutionize Remote Collaboration for Frontline Workers by Bringing On & Live on Cimo Next-gen Smart Glasses
14.9.2022 18:08:00 EEST | Business Wire | Press release
AMA (ISIN GB00BNKGC5 – ticker ALAMA), a pioneer in Assisted Reality solutions, and moziware, a provider of leading-edge wearable technologies of Industrial Metaverse today announced their global strategic partnership to reshape remote collaboration by combining AMA’s brand new XpertEye On & Live remote assistance solution with moziware’s next-gen cimo smart glasses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220905005199/en/
Strategic Partnership moziware - AMA
With AMA‘s XpertEye On & Live solution, it only takes just one click on cimo to start collaborating and benefit from full HD video quality with 1080p image resolution, extremely accurate white balance settings, and industrial noise cancellation. Equipped with AMA’s AR-powered remote collaboration solution and the cimo ultra-compact and lightweight smart glasses, frontline workers across manufacturing, audit, telco, healthcare, and other industries can remotely collaborate, complete complex tasks together, and resolve issues smarter, faster, and safer.
“moziware is honored to have AMA as our strategic partner. Through relentless teamwork, we have the latest XpertEye solution seamlessly integrated on cimo with exciting new features like one-button start. We believe the joint solution will revolutionize how frontline workers collaborate and operate in the industrial 4.0 era”, said Dr. Li Bo, CEO of moziware.
“AMA is proud to have teamed up with moziware since 2021 to propose today the latest in voice-activated, hands-free, remote collaboration. Our aggressively priced and easy-to-use solution will help improve safety, efficiency, and productivity of frontline workers around the world", said Christian Guillemot, co-founder and CEO of AMA.
About AMA
With eight years of proven experience in remote assistance solutions, AMA is helping medical institutions and industrial organizations of all sizes accelerate their digital transformation. Our market leading XpertEye Assisted Reality platform has been deployed in more than 100 countries, addressing a wide range of applications like remote diagnostics, inspection, scheduling, and workflow management. These unequaled remote interactive collaboration solutions empower our customers to improve productivity, speed up resolution time, and maximize uptime.
With offices in Europe, in the USA and in the APAC region, AMA can work in every time zone and reach its customers wherever they are.
AMA is listed on Euronext Growth Paris (GB00BNKGZC51 - ALAMA).
More information on www.amaxperteye.com
About mōziware
mōziware is a pioneer in accelerating digital transformation through leading-edge wearable technologies and solutions for the industrial sector and beyond.
Its mission is to create an ecosystem of solutions that leverage Augmented Reality (AR), Artificial Intelligence (AI), and Internet of Things (IoT) technologies to empower executives and frontline workers to make smarter, safer, and faster decisions, resulting in increased productivity, improved safety, optimized workflows, and reduced costs.
For more information, visit: https://moziware.io, contact us at info@moziware.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005199/en/
Contact information
AMA press contact
Esther Duval
Director Marketing & Communication
Tel: +33 689 182 343
esther.duval@ama.bzh
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GoldState Music and Bridgepoint Announce Strategic Partnership Targeting Growth Investments26.2.2026 14:00:00 EET | Press release
Bridgepoint, one of the world’s leading mid-market investors, today announced that it has entered into a strategic partnership with GoldState Music, a premier music investment platform, committing a significant investment as lead investor in GoldState’s Growth Strategy. The capital will support a dedicated investment programme focused on building and scaling high-quality music-oriented businesses globally. GoldState Music is a private investment firm founded in 2022 by industry veteran Charles Goldstuck, who played an integral role in the development of many music enterprises as well as in the careers of numerous major artists and songwriters. The company’s Growth Strategy is focused on investing in and scaling growing businesses operating in the music value chain, combining deep industry relationships with institutional investment discipline and structured capital solutions. Under the strategic partnership announced today, GoldState will originate and actively manage the Growth Strate
Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners26.2.2026 14:00:00 EET | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226378156/en/ Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Unlike high-performance racing watches that can feel overwhelming,
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 14:00:00 EET | Press release
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly expand our oncology pipeline with late-preclinical and Phase 1-ready assets in a multi-billion dollar market with substantial unmet medical needs. With this acquisition, if completed, we will strengthen our armamentari
Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery26.2.2026 13:49:00 EET | Press release
The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wyss Geneva’s Minimally Invasive Intracranial Access (MICA) research project in December 2024. Its flagship platform, Neuro Access, combines OCT imaging with advanced navigation to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.” Dr. Erwin Böttinger, CEO, Wyss Geneva “Neurosurg
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants26.2.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were issued on January 13, 2025, for proceeds of approximately $200 million. Upon exercise of these outstanding warrants, Compass Pathways is issuing 15,160,619 American Depositary Shares (“ADSs”) and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 19,898,829 ADSs. Compass Pathways currently intends to use the proceeds from these warrant exercises, together with its existing cash and cash equivalents, to fund ongoing COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 trial of COMP360 in PTSD, acceleration of its commercial readiness activities, and for working capital and general corporate purposes. The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on Februar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom